Pharmacists: Learn More About the First and Only FDA-Approved Liquid Losartan

Arbli™ (losartan potassium) oral suspension 10 mg/mL delivers ready-to-dispense, tailored dosing for patients with oral adherence hurdles.

Streamlining Care, Eliminating Complexity

Say goodbye to time-consuming losartan compounding. Arbli™ offers a ready-to-use, FDA-approved liquid losartan that simplifies your workflow. With 24-months of room-temperature stability (unopened), no refrigeration needed, and standardized 165 mL bottles, peppermint-flavored Arbli improves inventory management while providing a counseling opportunity for patients struggling with tablet adherence.

It’s enhanced patient care without the resource burden of extemporaneous preparation.

Additional information for pharmacists:

Arbli liquid losartan bottle on counter

Key Differences from Compounded Medications

Because compounded drugs are not FDA-approved, FDA does not verify their safety, effectiveness, or quality before they are marketed. In addition, poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient. This may potentially lead to serious patient injury and death.4

The only ready-to-use oral liquid losartan option on the market with a 24-month shelf life (unopened) and no refrigeration required.

Arbli oral suspension is similar in safety, efficacy, and side effect profile to COZAAR® (losartan potassium) 100 mg tablet.

Ready-to-dispense dosing formulation eliminates compounding and allows for a seamless transition to the outpatient setting.

Losartan Comparison Matrix

Arbli oral suspension1Compounded losartan suspension2
Dose10 mg/mL2.5 mg/mL
Ready-to-dispense FDA-approved formulationYESNO*
Compliant with Good Manufacturing PracticesYESCan vary†
Potency and Purity FDA Standards†MeetsCan vary†
Refrigeration requiredNO1YES2
Active Pharmaceutical Ingredients (API) by FDA-approved sourcesYESCan vary
Shaking requiredShake for 20 seconds before dispensing dose1Shake each time before use‡
Shelf lifeRoom-temperature for 60 days once opened§Once prepared, must be refrigerated, up to four weeks
At Retail PharmaciesYESCan vary

*FDA-approved labels provide preparation for 2.5 mg/mL suspension.
†FDA does not verify the safety or effectiveness of compounded drugs before they are marketed.
‡Shake 2 minutes before prep, let stand one hour, then shake again for one minute. Must shake again for one minute after diluent mixture added. Shake each time before use.2
§Keep container tightly closed. Protect from light. Once the bottle is opened, use it within 60 days.1

Indications & Usage

Arbli is an angiotensin II receptor blocker (ARB) indicated for:1

  • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old
  • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy
  • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension

Arbli is contraindicated for patients with hypersensitivity to any component. Arbli is also contraindicated for co-administration with aliskiren in patients with diabetes.

Elderly patient experiencing difficulty swallowing

Actor portrayal, not actual patient

Helpful Information for Pharmacists

Downloadable Resources
Frequently Asked Questions

References

1. ARBLITM [prescribing information]. Commack, NY: Scienture, LLC. 2025
2. COZAAR® label. Accessed on dailymed.nlm.nih.gov. COZAAR® label provides suspension is 2.5 mg/mL in 200 mL solution.
3. Data on file. Scienture, LLC. 2025
4. Food Drug Administration Center for Drug Evaluation & Research (2016). Guidance for Industry: Compounded Drug Products That Are Essentially Copies of a
Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDA, Maryland) 1-8. doi:10.1007/s40268-013-0005-9

COZAAR® is a registered trademark of N.V. Organon.